The prototypical inhibitor of cholesterol esterification, Sah 58-035 [3-[decyldimethylsilyl]-N-[2-(4-methylphenyl)-1-phenylethyl]propanamide], is an agonist of estrogen receptors

Journal of Pharmacology and Experimental Therapeutics

Volumn 319, Issue 1, 2006, Pages 139-149

  De Medina, Philippe ^a,d   Boubekeur, Nadia ^a   Balaguer, Patrick ^a   Favre, Gilles ^a,b,c   Silvente Poirot, Sandrine ^a,b,c   Poirot, Marc ^a,b,c  

^a INSERM   (France)

^b INSTITUT CLAUDIUS REGAUD   (France)

^c UNIVERSITÉ PAUL SABATIER   (France)

^d Affichem   (France)

Author keywords

[No Author keywords available]

Indexed keywords

3 DECYLDIMETHYLSILYL N [2 (4 METHYLPHENYL) 1 PHENYLETHYL]PROPIONAMIDE; ANTIESTROGEN; CHOLESTEROL ACYLTRANSFERASE; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; N BUTYL 11 (3,17BETA DIHYDROXYESTRA 1,3,5(10) TRIEN 7ALPHA YL) N METHYLUNDECANAMIDE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN DERIVATIVE;

ALZHEIMER DISEASE; ANIMAL CELL; ARTICLE; ATHEROSCLEROSIS; BINDING SITE; CANCER; CELL PROLIFERATION; CHOLESTEROL ESTERIFICATION; CONTROLLED STUDY; DATA ANALYSIS; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG TARGETING; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IC 50; LIGAND BINDING; MOLECULAR DYNAMICS; MOLECULAR MODEL; MOLECULAR SIZE; NONHUMAN; PRIORITY JOURNAL; PROTEIN STRUCTURE; RAT; STRUCTURE ANALYSIS; X RAY;

AMIDES; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; ENZYME INHIBITORS; ESTRADIOL; HUMANS; MODELS, MOLECULAR; ORGANOSILICON COMPOUNDS; POLYUNSATURATED ALKAMIDES; RECEPTORS, ESTROGEN; STEROL O-ACYLTRANSFERASE; TRANSCRIPTION, GENETIC;

EID: 33748992624     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.106.104349     Document Type: Article

References (38)

1. Anstead GM, Carlson KE, and Katzenellenbogen JA (1997) The estradiol pharmacophore: ligand structure-estrogen receptor binding affinity relationships and a model for the receptor binding site. Steroids 62:268-303.
2. Biberger C and von Angerer E (1996) 2-Phenylindoles with sulfur containing side chains: estrogen receptor affinity, antiestrogenic potency, and antitumor activity. J Steroid Biochem Mol Biol 58:31-43.
3. Brzozowski AM, Pike AC, Dauter Z, Hubbard RE, Bonn T, Engstrom O, Ohman L, Greene GL, Gustafsson JA, and Carlquist M (1997) Molecular basis of agonism and antagonism in the oestrogen receptor. Nature (Lond) 389:753-758.
4. Callige M, Kieffer I, and Richard-Foy H (2005) CSN5/Jab1 is involved in ligand-dependent degradation of estrogen receptor α by the proteasome. Mol Cell Biol 25:4349-4358.
5. Cory AH, Owen TC, Barltrop JA, and Cory JG (1991) Use of an aqueous soluble tetrazolium/formazan assay for cell growth assays in culture. Cancer Commun 3:207-212.
6. de Medina P, Favre G, and Poirot M (2004a) Multiple targeting by the antitumor drug tamoxifen: a structure-activity study. Curr Med Chem Anticancer Agents 4:491-508.
7. de Medina P, Payre BL, Bernad J, Bosser I, Pipy B, Silvente-Poirot S, Favre G, Faye JC, and Poirot M (2004b) Tamoxifen is a potent inhibitor of cholesterol esterification and prevents the formation of foam cells. J Pharmacol Exp Ther 308:1165-1173.
8. Dodds E, Goldberg L, and Lawson W (1938) Oestrogenic activity of alkylated stilboestrol. Nature (Lond) 142:34.
9. Doisneau-Sixou SF, Cestac P, Chouini S, Carroll JS, Hamilton AD, Sebti SM, Poirot M, Balaguer P, Faye JC, Sutherland RL, et al. (2003) Contrasting effects of prenyltransferase inhibitors on estrogen-dependent cell cycle progression and estrogen receptor-mediated transcriptional activity in MCF-7 cells. Endocrinology 144:989-998.
10. Fang H, Tong W, Branham WS, Moland CL, Dial SL, Hong H, Xie Q, Perkins R, Owens W, and Sheehan DM (2003) Study of 202 natural, synthetic, and environmental chemicals for binding to the androgen receptor. Chem Res Toxicol 16:1338-1358.
11. Hutter-Paier B, Huttunen HJ, Puglielli L, Eckman CB, Kim DY, Hofmeister A, Moir RD, Domnitz SB, Frosch MP, Windisch M, et al. (2004) The ACAT inhibitor CP-113,818 markedly reduces amyloid pathology in a mouse model of Alzheimer's disease. Neuron 44:227-238.
12. Jensen EV and Jordan VC (2003) The estrogen receptor: a model for molecular medicine. Clin Cancer Res 9:1980-1989.
13. Jordan VC (2003a) Antiestrogens and selective estrogen receptor modulators as multifunctional medicines: I. Receptor interactions. J Med Chem 46:883-908.
14. Jordan VC (2003b) Antiestrogens and selective estrogen receptor modulators as multifunctional medicines: II. Clinical considerations and new agents. J Med Chem 46:1081-1111.
15. Jordan VC, Schafer JM, Levenson AS, Liu H, Pease KM, Simons LA, and Zapf JW (2001) Molecular classification of estrogens. Cancer Res 61:6619-6623.
16. Joyeux A, Balaguer P, Germain P, Boussioux AM, Pons M, and Nicolas JC (1997) Engineered cell lines as a tool for monitoring biological activity of hormone analogs. Anal Biochem 249:119-130.
17. Kagechika H and Shudo K (2005) Synthetic retinoids: recent developments concerning structure and clinical utility. J Med Chem 48:5875-5883.
18. Kedjouar B, de Medina P, Oulad-Abdelghani M, Payre B, Silvente-Poirot S, Favre G, Faye JC, and Poirot M (2004) Molecular characterization of the microsomal tamoxifen binding site. J Biol Chem 279:34048-34061.
19. Kramer PR and Wray S (2002) 17-Beta-estradiol regulates expression of genes that function in macrophage activation and cholesterol homeostasis. J Steroid Biochem Mol Biol 81:203-216.
20. Levenson AS and Jordan VC (1998) The key to the antiestrogenic mechanism of raloxifene is amino acid 351 (aspartate) in the estrogen receptor. Cancer Res 58:1872-1875.
21. Long X and Nephew KP (2006) Fulvestran (ICI 182,780)-dependent interacting proteins mediate immobilization and degradation of estrogen receptor-α. J Biol Chem 281:9607-9615.
22. Maggiora GM and Johnson MA (1990) Concepts and Applications of Molecular Similarity, John Wiley & Sons, New York.
23. Matsuda K (1994) ACAT inhibitors as antiatherosclerotic agents: compounds and mechanisms. Med Res Rev 14:271-305.
24. Moggs JG and Orphanides G (2001) Estrogen receptors: orchestrators of pleiotropic cellular responses. EMBO (Eur Mol Biol Organ) Rep 2:775-781.
25. Nilsen J and Diaz Brinton R (2003) Mechanism of estrogen-mediated neuroprotection: regulation of mitochondrial calcium and Bcl-2 expression. Proc Natl Acad Sci USA 100:2842-2847.
26. Pare G, Krust A, Karas RH, Dupont S, Aronovitz M, Chambon P, and Mendelsohn ME (2002) Estrogen receptor-alpha mediates the protective effects of estrogen against vascular injury. Circ Res 90:1087-1092.
27. Paris F, Balaguer P, Terouanne B, Servant N, Lacoste C, Cravedi JP, Nicolas JC, and Sultan C (2002) Phenylphenols, biphenols, bisphenol-A and 4-tert-octylphenol exhibit alpha and beta estrogen activities and antiandrogen activity in reporter cell lines. Mol Cell Endocrinol 193:43-49.
28. Pike AC, Brzozowski AM, Walton J, Hubbard RE, Thorsell AG, Li YL, Gustafsson JA, and Carlquist M (2001) Structural insights into the mode of action of a pure antiestrogen. Structure (Camb) 9:145-153.
29. Poirot M, De Medina P, Delarue F, Perie JJ, Klaebe A, and Faye JC (2000) Synthesis, binding and structure-affinity studies of new ligands for the microsomal anti-estrogen binding site (AEBS). Bioorg Med Chem 8:2007-2016.
30. Revankar CM, Cimino DF, Sklar LA, Arterburn JB, and Prossnitz ER (2005) A transmembrane intracellular estrogen receptor mediates rapid cell signaling. Science (Wash DC) 307:1625-1630.
31. Rodriguez A, Bachorik PS, and Wee SB (1999) Novel effects of the acyl-coenzyme A:cholesterol acyltransferase inhibitor 58-035 on foam cell development in primary human monocyte-derived macrophages. Arterioscler Thromb Vasc Biol 19:2199-2206.
32. Ross AC, Go KJ, Heider JG, and Rothblat GH (1984) Selective inhibition of acyl coenzyme A:cholesterol acyltransferase by compound 58-035. J Biol Chem 259:815-819.
33. Shiau AK, Barstad D, Loria PM, Cheng L, Kushner PJ, Agard DA, and Greene GL (1998) The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 95:927-937.
34. Sliskovic DR, Picard JA, and Krause BR (2002) ACAT inhibitors: the search for a novel and effective treatment of hypercholesterolemia and atherosclerosis. Prog Med Chem 39:121-171.
35. Tosi MR and Tugnoli V (2005) Cholesteryl esters in malignancy. Clin Chim Acta 359:27-45.
36. Wakeling AE and Bowler J (1988) Biology and mode of action of pure antioestrogens. J Steroid Biochem 30:141-147.
37. Wise PM, Dubal DB, Rau SW, Brown CM, and Suzuki S (2005) Are estrogens protective or risk factors in brain injury and neurodegeneration? Reevaluation after the Women's Health Initiative. Endocr Rev 26:308-312.
38. Zablocki JA, Katzenellenbogen JA, Carlson KE, Norman MJ, and Katzenellenbogen BS (1987) Estrogenic affinity labels: synthesis, irreversible receptor binding, and bioactivity of aziridine-substituted hexestrol derivatives. J Med Chem 30:829-838.